Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.National University Corporation Kyoto University (Kyoto University) and Takeda Pharmaceutical Company have entered into a five-year partnership to discover drugs for CNS-acting drugs for obesity and schizophrenia.
Subscribe to our email newsletter
Under the terms of agreement, Kyoto University and Takeda will work closely to discover new drug targets and biomarkers for obesity and schizophrenia.
The two parties will conduct medical research for drug candidates by utilising the findings obtained at the Graduate School of Medicine and the University Hospital, and its worldwide networks.
Takeda Pharmaceutical chief scientific officer Shigenori Ohkawa said the company is very pleased to collaborate with Kyoto University.
"Through the close partnership on research and development, we expect that we will be able to create innovative drugs for obesity and schizophrenia where there is a high unmet need for patients," Ohkawa said.